Insertion of an SVA element, a nonautonomous retrotransposon, in PMS2 intron 7 as a novel cause of lynch syndrome

被引:41
|
作者
van der Klift, Heleen M. [1 ]
Tops, Carli M. [1 ]
Hes, Frederik J. [1 ]
Devilee, Peter [1 ,2 ]
Wijnen, Juul T. [1 ]
机构
[1] Leiden Univ, Ctr Human & Clin Genet, Med Ctr, Leiden, Netherlands
[2] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands
关键词
Lynch syndrome; LINE-1-mediated retrotransposition; SVA; PMS2; HUMAN GENETIC-DISEASE; MUTATION; EVENTS; INSTABILITY; RETROPOSON; HUMANS; HNPCC; MSH2;
D O I
10.1002/humu.22092
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Heterozygous germline mutations in the mismatch repair gene PMS2 predispose carriers for Lynch syndrome, an autosomal dominant predisposition to cancer. Here, we present a LINE-1-mediated retrotranspositional insertion in PMS2 as a novel mutation type for Lynch syndrome. This insertion, detected with Southern blot analysis in the genomic DNA of the patient, is characterized as a 2.2 kb long 5' truncated SVA_F element. The insertion is not detectable by current diagnostic testing limited to MLPA and direct Sanger sequencing on genomic DNA. The molecular nature of this insertion could only be resolved in RNA from cultured lymphocytes in which nonsense-mediated RNA decay was inhibited. Our report illustrates the technical problems encountered in the detection of this mutation type. Especially large heterozygous insertions will remain unnoticed because of preferential amplification of the smaller wild-type allele in genomic DNA, and are probably underreported in the mutation spectra of autosomal dominant disorders. Hum Mutat 33:10511055, 2012. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:1051 / 1055
页数:5
相关论文
共 50 条
  • [41] Ovarian uveal melanoma metastasis showing MLH1/PMS2 protein loss in a patient with Lynch Syndrome
    Lobo, J.
    Pinto, C.
    Freitas, M.
    Vieira, R.
    Machado, B.
    Pinheiro, M.
    Vizcaino, R.
    Oliva, E.
    Teixeira, M. R.
    Jeronimo, C.
    Bartosch, C.
    VIRCHOWS ARCHIV, 2016, 469 : S101 - S101
  • [42] MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer
    Bente A Talseth-Palmer
    Mary McPhillips
    Claire Groombridge
    Allan Spigelman
    Rodney J Scott
    Hereditary Cancer in Clinical Practice, 8
  • [43] Evaluation of Prediction Models for Lynch Syndrome: Updating the PREMM1,2,6 Model to Identify PMS2 Mutation Carriers
    Goverde, Anne
    Spaander, Manon
    Nieboer, Daan
    van den Ouweland, Ans
    Dinjens, Winand
    Dubbink, Hendrikus J.
    Tops, Carli M.
    Bruno, Marco J.
    Hofstra, Robert M.
    Steyerberg, Ewout
    Wagner, Anja
    GASTROENTEROLOGY, 2016, 150 (04) : S360 - S361
  • [44] Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2)
    Rahner, Nils
    Steinke, Verena
    Schlegelberger, Brigitte
    Olschwang, Sylviane
    Eisinger, Francois
    Hutter, Pierre
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2010, 18 (09) : 1071 - 1071
  • [45] Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2)
    Nils Rahner
    Verena Steinke
    Brigitte Schlegelberger
    Sylviane Olschwang
    François Eisinger
    Pierre Hutter
    European Journal of Human Genetics, 2010, 18 : 1071 - 1071
  • [46] Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2
    Sigurdis Haraldsdottir
    Thorunn Rafnar
    Wendy L. Frankel
    Sylvia Einarsdottir
    Asgeir Sigurdsson
    Heather Hampel
    Petur Snaebjornsson
    Gisli Masson
    Daniel Weng
    Reynir Arngrimsson
    Birte Kehr
    Ahmet Yilmaz
    Stefan Haraldsson
    Patrick Sulem
    Tryggvi Stefansson
    Peter G. Shields
    Fridbjorn Sigurdsson
    Tanios Bekaii-Saab
    Pall H. Moller
    Margret Steinarsdottir
    Kristin Alexiusdottir
    Megan Hitchins
    Colin C. Pritchard
    Albert de la Chapelle
    Jon G. Jonasson
    Richard M. Goldberg
    Kari Stefansson
    Nature Communications, 8
  • [47] MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer
    Roberts, Maegan E.
    Jackson, Sarah A.
    Susswein, Lisa R.
    Zeinomar, Nur
    Ma, Xinran
    Marshall, Megan L.
    Stettner, Amy R.
    Milewski, Becky
    Xu, Zhixiong
    Solomon, Benjamin D.
    Terry, Mary Beth
    Hruska, Kathleen S.
    Klein, Rachel T.
    Chung, Wendy K.
    GENETICS IN MEDICINE, 2018, 20 (10) : 1167 - 1174
  • [48] Low-grade glioma with novel mutations in KRAS and PMS2 in an adolescent with Down syndrome
    Adams, Jason W.
    Malicki, Denise
    Levy, Michael
    Crawford, John Ross
    BMJ CASE REPORTS, 2021, 14 (08)
  • [49] Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2
    Haraldsdottir, Sigurdis
    Rafnar, Thorunn
    Frankel, Wendy L.
    Einarsdottir, Sylvia
    Sigurdsson, Asgeir
    Hampel, Heather
    Snaebjornsson, Petur
    Masson, Gisli
    Weng, Daniel
    Arngrimsson, Reynir
    Kehr, Birte
    Yilmaz, Ahmet
    Haraldsson, Stefan
    Sulem, Patrick
    Stefansson, Tryggvi
    Shields, Peter G.
    Sigurdsson, Fridbjorn
    Bekaii-Saab, Tanios
    Moller, Pall H.
    Steinarsdottir, Margret
    Alexiusdottir, Kristin
    Hitchins, Megan
    Pritchard, Colin C.
    de la Chapelle, Albert
    Jonasson, Jon G.
    Goldberg, Richard M.
    Stefansson, Kari
    NATURE COMMUNICATIONS, 2017, 8
  • [50] Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers
    Goverde, A.
    Spaander, M. C. W.
    Nieboer, D.
    van den Ouweland, A. M. W.
    Dinjens, W. N. M.
    Dubbink, H. J.
    Tops, C. J.
    ten Broeke, S. W.
    Bruno, M. J.
    Hofstra, R. M. W.
    Steyerberg, E. W.
    Wagner, A.
    FAMILIAL CANCER, 2018, 17 (03) : 361 - 370